Certain brachytherapy dose distributions, such as those for LDR prostate implants, are readily modeled by treatment planning systems ͑TPS͒ that use the superposition principle of individual seed dose distributions to calculate the total dose distribution. However, dose distributions for brachytherapy treatments using high-Z shields or having significant material heterogeneities are not currently well modeled using conventional TPS. The purpose of this study is to establish a new treatment planning technique ͑Tufts technique͒ that could be applied in some clinical situations where the conventional approach is not acceptable and dose distributions present cylindrical symmetry. Dose distributions from complex brachytherapy source configurations determined with Monte Carlo methods were used as input data. These source distributions included the 2 and 3 cm diameter Valencia skin applicators from Nucletron, 4-8 cm diameter AccuBoost peripheral breast brachytherapy applicators from Advanced Radiation Therapy, and a 16 mm COMS-based eye plaque using Cs seeds. Radial dose functions and 2D anisotropy functions were obtained by positioning the coordinate system origin along the dose distribution cylindrical axis of symmetry. Origin:tissue distance and active length were chosen to minimize TPS interpolation errors. Dosimetry parameters were entered into the PINNACLE TPS, and dose distributions were subsequently calculated and compared to the original Monte Carlo-derived dose distributions. The new planning technique was able to reproduce brachytherapy dose distributions for all three applicator types, producing dosimetric agreement typically within 2% when compared with Monte Carlo-derived dose distributions. Agreement between Monte Carlo-derived and planned dose distributions improved as the spatial resolution of the fitted dosimetry parameters improved. For agreement within 5% throughout the clinical volume, spatial resolution of dosimetry parameter data Յ0.1 cm was required, and the virtual brachytherapy source data set included over 5000 data points. On the other hand, the lack of consideration for applicator heterogeneity effect caused conventional dose overestimates exceeding an order of magnitude in regions of clinical interest. This approach is rationalized by the improved dose estimates. In conclusion, a new technique was developed to incorporate complex Monte Carlo-based brachytherapy dose distributions into conventional TPS. These results are generalizable to other brachytherapy source types and other TPS.
I. INTRODUCTION
The American Association of Physicist in Medicine ͑AAPM͒ Task Group No. 43 ͑TG-43͒ brachytherapy dosimetry formalism is well established [1] [2] [3] and permits calculation of dose distributions for diverse circumstances including low-dose rate ͑LDR͒ permanent prostate implants, gynecological implants using temporary high-dose rate ͑HDR͒ 192 Ir implants, and temporary episcleral plaque brachytherapy procedures. Conventional treatment planning systems ͑TPS͒ use the AAPM TG-43 brachytherapy dose calculation formalism which is based on applying the source superposition principle to cylindrically symmetric single-source photonemitting brachytherapy dose distributions throughout a clinically defined volume. Modern TPS software is able to generate high-resolution dose distributions and dose volume histograms ͑DVHs͒ based on user-defined source positions and regions of interest. The conventional brachytherapy TPS algorithm is best suited where:
͑i͒ source:source shielding is negligible, ͑ii͒ water is radiologically equivalent to tissue over the appropriate photon energy range, ͑iii͒ high-Z shields or low material densities ͑e.g., air͒ are not present, and ͑iv͒ when the scattering conditions for the clinical circumstances are similar to those present for acquisition of the initial, single-source brachytherapy dose distributions obtained using either measurements or Monte Carlo ͑MC͒ methods. [4] [5] [6] This conventional approach works well for calculation of single-source dose distributions in unbounded water media. However, in clinical situations where complex brachytherapy sources or applicators with high-Z shielding or boundedphantom configurations are present, the requirements listed in ͑i͒-͑iv͒ are not met and consequently will detract from accurate calculation of clinical brachytherapy dose distributions. In fact, it is not possible in some instances to perform treatment planning using the conventional approach. Advanced brachytherapy dose calculation techniques based on collapsed cone or MC methods are promising, [7] [8] [9] but their use is not widespread and there is a need to bolster currently available techniques.
The purpose of this study is to establish a new treatment planning technique ͑referred to henceforth as the Tufts technique͒ that could be applied in clinical situations where the conventional approach is not acceptable and dose distributions present cylindrical symmetry. Using conventional brachytherapy TPS, the Tufts technique allows one to replicate dose distributions obtained by Monte Carlo methods for complex multi-source applicators containing high-Z shielding for bounded phantom configurations with a "virtual source" using a modified TG-43 formalism ͑using either the standard polar or the cylindrical coordinates systems͒. [10] [11] [12] Clinical implementation of the Tufts technique for three brachytherapy treatment modalities is described where conventional TPS calculations ͑based on single-source input data͒ are inadequate.
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II. MATERIALS AND METHODS
II.A. Treatment planning with the Tufts technique
Monte Carlo dose distributions for complex configurations are generally not formatted in the geometry of singlesource dose distributions for which the TG-43 dosimetry formalism is defined. Thus, the Tufts technique converts collimated, cylindrically symmetric dose distributions for complex treatment configurations to the TG-43 formalism as a virtual source. The virtual source could subsequently be applied in the TPS to replicate the MC-derived dose distribution from the applicator. The steps required to obtain TG-43 data for virtual sources are as follows:
͑i͒ Identify the dose distribution cylindrical axis of symmetry; ͑ii͒ select an active length L; ͑iii͒ derive a radial dose function g͑r͒ along the virtual source long axis, and determine the origin where the virtual source center will be located; ͑iv͒ derive the 2D anisotropy function F͑r , ͒; and ͑v͒ choose a virtual dose rate constant ⌳ at the reference point to reproduce Monte Carlo-calculated dose values using the above parameters.
In the present study, g͑r͒ and F͑r , ͒ were obtained by positioning the coordinate system origin of the virtual source along the dose distribution cylindrical axis of symmetry ͑i.e., z axis͒ as shown in Fig. 1 . Distance along this axis between the patient surface z surface and coordinate system origin of the virtual source was set to minimize g͑r͒ interpolation errors and roughly approximated the average position of the source͑s͒ used in the applicators. The depth d into the patient and the distance from the virtual source to z surface are related by d = z − z surface except for the eye plaque where d = z − z surface − 0.1 cm.
In some brachytherapy applications, the sources are positioned outside the patient at a radial distance greater than the AAPM TG-43 normalization reference point ͑r 0 =1 cm͒. This was the case for the Valencia and AccuBoost applicators ͑see below͒. For the conventional TG-43 dose calculation formalism, g͑r͒ is normalized at this reference point. However, dose calculation at this location is of limited interest if it is positioned outside the patient.
The virtual source L was selected with a very small value ͑L = 0.01 cm͒ in order to define the virtual source as linear and include F͑r , ͒ in the calculation of dose distributions. This method, i.e., to use the 2D brachytherapy dosimetry FIG. 1. Treatment planning coordinate system indicating origin position for the virtual source. The 2D anisotropy could be represented as either F͑r , ͒ or F͑x , z͒. Radial distance r and polar angle are defined as for the AAPM TG-43 polar coordinate system. The cylindrical coordinate system includes parameters such as z distance from the virtual source along the z axis and x distance normal to and measured from the z axis.
formalism with a point-source geometry function, was previously described by Rivard et al. for an anisotropic pointlike brachytherapy source, 13 the purpose of the current approach was to minimize g͑r͒ interpolation errors while using F͑r , ͒ instead of an ͑r͒.
Because the applicators were oriented with a central axis into the patient along =0°͑Fig. 1͒, g͑r͒ was derived to account for dose falloff and attenuation along the central axis ͑i.e., z axis͒. After calculating g͑r͒ along the longitudinal axis using
F͑r , ͒ was selected to minimize differences with the original MC data. Although g͑r͒ was derived along = 0°, it was introduced in the TPS as if it was derived along the standard profile of 0 = 90°. Because the dose profile used to obtain g͑r͒ in the Tufts technique was along = 0°, F͑r , =0°͒ was set to unity for dose profile reproduction along the axis of symmetry, and F͑r , 0 = 90°͒ was also set to unity for consistency with the TG-43 formalism. One should note that for the examples presented herein, dose derived along the x axis ͑ 0 = 90°͒ was located outside the patient and not of clinical relevance. Finally, a value for the dose rate constant ⌳ was selected in order to reproduce the absolute MC data using the pointlike geometry factor and the derived g͑r͒ and F͑r , ͒ values.
II.B. Brachytherapy devices characteristics
In this proof-of-concept study, the applicators assessed in this work were the Valencia skin applicators ͑Nucletron B.V., Veenendaal, The Netherlands͒, 14 the AccuBoost breast applicators ͑Advanced Radiation Therapy, Billerica, MA͒, 15 and the collaborative ocular melanoma study ͑COMS͒ eye plaques. 16 Except very close to the eye plaque or due to HDR 192 Ir source polar angle anisotropy for the Valencia applicator, dose distributions were readily approximated as cylindrically symmetric. Limitations of this approach are discussed later.
II.B.1. Valencia applicators
The Valencia applicators are cone-shaped applicators made of tungsten alloy designed to treat skin tumors.
14 These applicators are accessories of the Selectron HDR 192 Ir unit. The Valencia applicators are 2 cm and 3 cm in diameter and are referred to as model VH2 and VH3, respectively. In Fig.  2 , a schematic view of the VH2 applicator is shown together with its corresponding MC-based isodose curves.
14 The HDR
192
Ir source is located 1.6 cm from the applicator outside the surface and moved in parallel to the skin surface. A tungstenalloy aperture collimates the 192 Ir emissions, and a tungstenalloy flattening filter makes uniform the dose profiles at a given depth unlike the similarly designed Leipzig applicator. 17, 18 Dose distributions for these applicators were obtained by Granero et al. using the GEANT4 MC code. 14, 19 Dose distributions were calculated every 0.05 cm in depth and radial extent for a right cylinder of radius R = 5 cm and height H = 5 cm. Since the most superficial voxel was bounded by xz planes from 0 Յ d Յ 0.050 cm, dose calculated in this voxel was assigned an average depth of 0.025 cm. Voxel depths increased sequentially by 0.050 cm. With dose simulated in this cylindrical coordinate system, the centrally positioned voxel was bound by radii of 0-0.050 cm, increasing sequentially by 0.050 cm. The cylindrical radii were assigned positions of 0.025, 0.075, 0.125 cm, . . .. Further description of the high-resolution calculation grid can be found in Ref. 14. For the conventional planning approach, a single HDR 192 Ir source was positioned 1.6 cm distant and in parallel to the patient surface.
II.B.2. AccuBoost applicators
The AccuBoost applicators administer radiation from an HDR 192 Ir brachytherapy source in a noninvasive manner for peripheral treatment of breast cancer. 15 The applicators are made of tungsten alloy and are shaped as an open right cylinder ͑Fig. 3͒. A catheter to direct an HDR 192 Ir source follows the inside circular edge forming a ring of dwell positions in order to collimate 192 Ir photons and apply dose uniformly ͑dwell step of 10 mm circumferentially͒. The distance from patient skin surface to circular ring plane for HDR 192 Ir dwells is 2.675 cm. As with the Valencia applicators, these AccuBoost applicators come in different diameters, models SBA-4, SBA-5, SBA-6, SBA-7, and SBA-8 for 4, 5, 6, 7, and 8 cm diameter applicators, respectively. However, the AccuBoost applicators are designed for treatment of deep-seated lesions using opposing beams and are compat- ible with available HDR 192 Ir systems. The position of the applicators is determined using mammographic image guidance which is integrated into the treatment platform. Dose distributions for the AccuBoost applicators were determined using the MCNP5 MC code. 15, 20 Voxels were oriented with cylindrical geometry spaced every 0.1 cm in a right cylindrical breast phantom with R = 15 cm and H = 8 cm.
II.B.3. COMS eye plaques
The COMS eye plaques contain a silastic seed carrier to accommodate low-energy LDR photon-emitting seeds. 21 A gold-alloy backing is used to shield radiation not directed to the eye lesion. Different plaque diameters with different seed configurations are available depending on the extent and position of the lesion. Dose distributions in homogeneous and heterogeneous media have been obtained for 103 Pd, 125 I, or 131 Cs seeds by Melhus and Rivard using the MCNP5 MC code. 16, 20 However, additional MC simulations using the same approach were performed for this study using depths ranging from Ϫ0.1 cm ͑i.e., outer sclera͒ to 3.06 cm in 0.02 cm increments for H = 3.16 cm and R = 1.5 cm in 0.05 cm increments in a 15 cm radius spherical water phantom. Further, the number of histories was increased to 10 9 histories for ϳ0.4% statistical uncertainties at a depth of 0.5 cm.
II.C. Dose calculation and comparison method
Dosimetry parameters deduced using the Tufts technique were entered into the PINNACLE TPS ͑version 8.0dp1, Cleveland, OH͒. For calculation of 2D dose distributions, PIN-NACLE can permit 2D parameter entry of polar coordinate system F͑r , ͒ data or cylindrical coordinate system F͑x , z͒ data. While brachytherapy dose calculations using cylindrical coordinate systems have been previously considered 10 and both coordinate systems were demonstrated to work adequately, the cylindrical coordinate system is presented to match the format of MC-based results for the three applicator types examine. Values for ⌳ were chosen to correlate PIN-NACLE results with simulated absolute dose rates. Thus, the MC-derived dose distribution for a complex arrangement of materials and radiation sources was reduced to one virtual source in an FDA-approved conventional TPS.
For the Valencia applicators, the g͑r͒ data entered into PINNACLE were in the range 1.0Յ r Յ 8.4 cm with 0.2 cm increments. Due to the solid angle of a single HDR 192 Ir source, a 1 / r 2 geometry function fitted the dose falloff and permitted 0.2 cm g͑r͒ increments. The cylindrical coordinate system F͑x , z͒ data were in the ranges 0.025Յ x Յ 4.975 cm and 1.625Յ z Յ 6.575 cm, both with 0.05 cm increments. Thus, 38 and 10 000 data points were used for g͑r͒ and F͑x , z͒ characterizations, respectively. From these data, the virtual source origin for both applicators ͑i.e., VH2 and VH3͒ was set to z surface = 1.6 cm.
The g͑r͒ data entered into PINNACLE for the AccuBoost applicators were in the range 1 Յ r Յ 18.4 cm with 0.1 cm increments. Accounting for the 0.275 cm thick compression paddle, z surface = 2.675 cm. The cylindrical coordinate system F͑x , z͒ data were in the ranges 0 Յ x Յ 15 cm and 2.675Յ z Յ 10.675 cm, both with 0.1 cm increments. Thus, 161 and 12 231 data points were used for g͑r͒ and F͑x , z͒ characterizations, respectively. For the conventional source technique, a ring of HDR 192 Ir model V2 sources ͑1 cm circumferential dwell spacing͒ was positioned at z = 0 and in parallel to the phantom surface with z surface = 2.675 cm.
In the case of the COMS eye plaques, distances from patient eye surface to the virtual source origin ͑z surface ͒ were set at 0.4, 0.5, and 0. 6 Cs, g͑r͒ data were in the ranges 0.4Յ z Յ 3.56 cm and 0.5Յ z Յ 3.66 cm, respectively, and had the same spatial resolution and cylindrical range F͑x , z͒. Thus, for each radionuclide examined, 176 and 4929 data points were used for g͑r͒ and F͑x , z͒ characterizations, respectively. For the conventional source superposition technique, the dose calculation method described by Rivard et al. was utilized. 22 Once brachytherapy dosimetry parameters were entered into PINNACLE, treatment plans using these data were performed to compare the original MC data to resultant dose calculations using the Tufts technique, as well as conventional brachytherapy dose calculations based on the standard TG-43 brachytherapy dosimetry formalism. While generally important only for isodose line visualization, 23 the TPS dose calculation grid was set to 0.1 cm to minimize volumetric averaging perturbations. Using PINNACLE, dose values for the FIG. 3 . Dose distribution comparison of PINNACLE output using the Tufts technique ͑left͒ and conventional planning ͑right͒ for the 6 cm diameter AccuBoost applicator. These results were representative of comparisons for all five round AccuBoost applicators, indicating significant differences between the Tufts technique and the conventional source superposition principle approach. From the bottom curves, the isodose lines are 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, and 120%.
calculation points were independent of dose grid resolution, size, and position. A quantitative comparison was made by positioning dose calculation points throughout the irradiated volume. The location of these points is specified in Table I . Points without dose listed in the table were positioned within the plaque. For the Valencia, AccuBoost, and COMS applicators, dose rate was normalized to 100% at depths of 0.3, 1.0, and 0.5 cm along the central axis, respectively. While not directly related to clinical prescriptions, this normalization approach permitted simple derivation of differences between the three techniques. Dose rates at these points obtained from either the Tufts technique, D Tufts , or the conventional TG-43 based approach, D TG-43 , were compared to the original MC data
Agreement between the planning methods was evaluated using two criteria: 1.00Ϯ 0.02 ͑i.e., Ϯ2%͒ based on AAPM TG-56 recommendations ͑Sec. II.A.4͒ 24 or a more generous criterion of 1.00Ϯ 0.05 ͑i.e., Ϯ5%͒ was used to determine sensitivity of agreement to a threshold value.
III. RESULTS
Though the source input and dose calculation grid sizes were much smaller than typically used for external beam treatment planning, time needed to calculate dose was less than 1 s in all cases since the complex dose distribution for one virtual source was precalculated during the virtual source commissioning phase and data were stored in the TPS.
III.A. Valencia applicator
The original MC-derived dose data and the Tufts technique doses are shown in Fig. 2 for the VH2 applicator. For the 56 points used for comparison ͑see Table I͒, the maximum and minimum D Tufts / D MC ratios were 1.019 and 0.971 for the VH2 and 1.049 and 0.971 for the VH3. Differences were attributed to grid coarseness in the gradient region since the largest differences occurred in the high-gradient penumbral region for the VH3 applicator. While 13 points ͑or 12%͒ of the 112 points in total were outside the Ϯ2% AAPM TG-56 criterion for agreement, none were outside Ϯ5%.
The conventional planning approach did not account for ͑i͒ material heterogeneities such as air in the applicator, the flattening filter which significantly changed the dose profile and dose rate within the collimated aperture, or the plastic cover to absorb electrons nor ͑ii͒ the significant attenuation of dose within the tungsten-alloy collimated regions. For the 56 points used to compare dose, the maximum and minimum D TG-43 / D MC ratios were 9.3 and 0.7 for the VH2 and 9.0 and 0.5 for the VH3. Again, the largest differences occurred in the high-gradient penumbral region for the applicators. Of the 112 sampling points in total, 98 ͑or 88%͒ were outside the Ϯ2% AAPM TG-56 criterion for agreement, and 83 points ͑or 74%͒ were outside Ϯ5%. Thus, the conventional approach did not accurately predict the MC-based dose distributions in contrast to the Tufts technique.
III.B. AccuBoost applicator
For the 64 points used to compare dose, the maximum and minimum D Tufts / D MC ratios over the 320 sampling points for all five applicators were 1.004 and 0.995, respectively. Differences were attributed to MC statistical uncertainties ͑typically ϳ0.1%͒ and g͑r͒ curve fitting. Because the dose obtained using the Tufts technique for the 320 sampling points for all five applicators were within Ϯ0.5%, the Ϯ2% AAPM TG-56 criterion was easily achieved.
Using the conventional planning approach with rings of HDR Cs seeds, respectively. In each image, the left-hand side is the Tufts technique and the right-hand side is the conventional TG-43 approach. The z axis points from the virtual source to the outer sclera ͑d = −0.1 cm͒. From the bottom curves, the isodose lines are 5%, 7.5%, 10%, 15%, 20%, 30%, 40%, 50%, 75%, 100%, 150%, 200%, 250%, 300%, and 350%. treatment planning approach sometimes either over-or underestimated the dose rate by a factor of 10 or 3, respectively. Of the 320 sampling points in total, 297 ͑or 93%͒ were outside the Ϯ2% AAPM TG-56 criterion for agreement, and 257 points ͑or 80%͒ were outside Ϯ5%. Again, the conventional planning approach did not accurately predict the MC-based dose distributions ͑Fig. 3͒. The reader is reminded that the Tufts technique accounted for the clinical environment with dose to breast tissue while the conventional TPS algorithm produced dose to water.
III.C. COMS eye plaques
Of Cs, respectively. Thus, the conventional treatment planning approach did not accurately predict the MC dose distributions as did the Tufts technique ͑Fig. 4͒.
IV. DISCUSSION
While the Tufts technique can be extended to other source configurations such as for the cylindrical dose distribution of an HDR 192 Ir vaginal cylinder or elongated brachytherapy sources, this study focused on demonstrating validity of the method to three brachytherapy applicators. The three applicators examined in this study were chosen particularly due to limitations of conventional brachytherapy treatment planning methods to accurately depict dose distributions. Once a data set is considered as a reference for clinical dosimetry, such as the MC tabulated values, the goal is to reproduce it as closely as possible with the TPS. A distinction of the Tufts technique is that extrapolation is not used. This conservative approach is especially beneficial in regions where the conventional TG-43 based extrapolations may not apply. Agreement with MC results using the Tufts technique was best along the axis of dose symmetry and in areas of uniform dose and was worse near the applicator edge in regions of high-dose gradients. Further, agreement between MC and planned dose distributions improved as the spatial resolution of the fitted dosimetry parameters improved. While the largest errors occurred in the highest dose gradient regions, overall errors reduced from a factor of 10 to just a few percentage.
For example, the dose distributions for the COMS eye plaques were initially taken from Melhus and Rivard, 16 having about 1400 data points in total but were resimulated to express over 5000 data points to improve spatial resolution in the high-dose gradient region. This task resulted in Tufts technique agreement with the original MC-derived dose improving from about 4% disparities to about 1% disparities. Even with 3D orientation and positioning of the three different seed types, dose calculations using the conventional source superposition principle are somewhat limited and could not account for material heterogeneities such as the silastic seed holder nor the significant attenuation of dose within the gold-alloy collimated regions. Again, dose to nonwater tissues could be simulated and clinically implemented with the Tufts technique. However, notched eye plaques for placement near the optic nerve may not be adequately characterized using the aforementioned methods due to lack of cylindrical symmetry. The MC-derived dose distributions were averaged over a given radial distance around the central axis. This radial volume averaging may lead to differences at specific points near the eye plaques within the calculation volume. By design, the Valencia and AccuBoost applicators are cylindrically symmetric. Similarly, the polygon shapes used in COMS seed holders were carefully chosen to ensure cylindrical dose symmetry along the central/prescriptive axis. As the distance from the eye plaque decreased or as the plaque size decreases, local dose variations attributed to individual seeds will dominate the overall dose distribution at close distances. For the 16 mm eye plaque studied, based on comparing rectilinear mesh data with cylindrically symmetric data at x = 0.5 cm, we estimate volume averaging to be less than 2% at a depth of 0.3 cm, ϳ10% at the inner sclera ͑0.0 cm͒, and possibly higher immediately beneath a seed ͑d Ͻ 0 cm͒.
V. CONCLUSION
A new technique was developed to implement complex MC-based brachytherapy dose distributions using conventional TPS. Typical agreement of Tufts technique to MC results was within 1% for all three brachytherapy applicator types examined. These results should be generalizable to other cylindrically symmetric brachytherapy sources and configurations or to other TPS. Further, in contrast to the conventional TPS algorithm, the Tufts technique could be applied to calculate dose to a specific tissue type ͑e.g., lung, bone, and prostate gland͒ instead of dose to liquid water as used in the TG-43 formalism. Until advanced brachytherapy dosimetry algorithms become widespread and readily available, the technique described herein may allow users of conventional brachytherapy planning systems which utilize the AAPM TG-43 2D formalism to clinically implement MCbased characterizations of complex, cylindrically symmetric brachytherapy implants. 
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